EUVIMEDEUVIMED entdecken
Crossref

Reply to Singh et al.

Kornpong Vantanasiri, Prasad G Iyer

Endoscopy · 01.05.2025 · 57 (05) · 571-572

DOI: 10.1055/a-2511-1951 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Endoscopy, erschienen am 01.05.2025. Verfasst von Kornpong Vantanasiri und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Mayo Clinic, Scottsdale, United States.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Letter to: Comparing recurrence rates between endoscopic mucosal resection and endoscopic submucosal dissection in Barrett’s endoscopic therapy: patient perspective matters! Endoscopy 2025; 57(05): 571-571 DOI: 10.1055/a-2496-7246 We appreciate the comments by Singh et al. regarding our editorial on recurrence rates following endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD) for treatment of dysplastic Barrett’s esophagus (BE). Their emphasis on the patient perspective raises a critical and often underrepresented consideration in clinical decision making. However, we respectfully assert that the patient-centered outcomes and evidence-based clinical endpoints are not mutually exclusive, and both perspectives must guide treatment strategies in BE management. We do not question the clinical relevance of achieving en bloc resection with ESD. In an ideal world, every nodular BE lesion should be removed en bloc to allow optimal histopathological assessment of lateral and deep resection margins. However, this is not possible in the real world. The primary objective of our editorial was to highlight that true recurrence should only be determined once complete remission of intestinal metaplasia (CRIM) – the primary endpoint of endoscopic eradication therapy recommended by all gastrointestinal society guidelines – has been achieved. This distinction is essential for differentiation of true recurrence from residual disease after initial endoscopic resection. Without distinguishing residual disease from true recurrence, studies risk overestimating the recurrence burden and, consequently, overestimating the clinical benefits of ESD over EMR. In real-world practice, the relevant clinical endpoint must take into account the fact that all patients with residual BE will undergo subsequent ablative therapy after endoscopic resection to eradicate all dysplastic and nondysplastic BE mucosa. Hence, we maintain that CRIM remains the most clinically meaningful endpoint for assessing recurrence in BE management and encourage future research to integrate both clinical and patient-centered outcomes to guide best treatment practices. Publication History Article published online: 22 April 2025 © 2025. Thieme. All rights reserved. Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

Autor:innen und Institutionen

  • Division of Gastroenterology and Hepatology, Mayo Clinic, Scottsdale, United States.

Zitieren

APA

Vantanasiri, K., & Iyer, P. G. (2025). Reply to Singh et al. Endoscopy, 57(05), 571-572. https://doi.org/10.1055/a-2511-1951

Vancouver

Vantanasiri K, Iyer PG. Reply to Singh et al. Endoscopy. 2025;57(05):571-572. doi:10.1055/a-2511-1951

BibTeX
@article{Vantanasiri2025,
  author = {Vantanasiri, Kornpong and Iyer, Prasad G},
  title = {Reply to Singh et al},
  journal = {Endoscopy},
  year = {2025},
  volume = {57},
  number = {05},
  pages = {571--572},
  doi = {10.1055/a-2511-1951}
}
Kostenlos starten →